Want to see IN:SUVEN full AI Analyst Report?
Top Page
Suven Life Sciences Limited
(SUVEN)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹321.00
▲(94.55% Upside)
Action:Reiterated
Date:07/10/26
The score is held down primarily by weak financial performance (recurring losses and persistent negative free cash flow, with deterioration in FY2025–FY2026). Strong technical momentum provides meaningful support, but valuation remains constrained due to negative earnings and no dividend data.
Positive Factors
R&D-driven business model and IP generation
Suven's core model centers on drug discovery and generating chemical entities/IP in CNS areas. That capability is a durable strategic asset: owning discovery expertise and IP enables licensing, partnerships, or milestone-driven cash inflows over multiple years if candidates progress, supporting long-term optionality.
Negative Factors
Persistent operating and net losses
Recurring operating and net losses indicate the business is not yet generating sustainable profits. Over months this erodes retained capital, forces reliance on external funding or dilution, and constrains reinvestment in development programs—limiting ability to convert discovery capabilities into long-term shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
R&D-driven business model and IP generation
Suven's core model centers on drug discovery and generating chemical entities/IP in CNS areas. That capability is a durable strategic asset: owning discovery expertise and IP enables licensing, partnerships, or milestone-driven cash inflows over multiple years if candidates progress, supporting long-term optionality.
Read all positive factors
Suven Life Sciences Limited (SUVEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹106.88B
Dividend Yield11.14%
Average Volume (3M)66.68K
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue Growth17.26%
EPS Growth-68.16%
CountryIN
Employees141
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-12.41
Shares Outstanding282,562,680
10 Day Avg. Volume55,337
30 Day Avg. Volume66,676
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)5.07
Price to Sales (P/S)421.72
P/FCF Ratio-9.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Suven Life Sciences Limited Business Overview & Revenue Model
Company Description
Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative c...
How the Company Makes Money
null...
Suven Life Sciences Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
9
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 71.15M | 66.56M | 116.93M | 135.39M | 118.44M |
| Gross Profit | -419.28M | -276.33M | 108.69M | 129.74M | -137.31M |
| EBITDA | -2.71B | -1.55B | -992.78M | -1.11B | -1.17B |
| Net Income | -2.76B | -1.61B | -1.05B | -1.18B | -1.22B |
Balance Sheet | |||||
| Total Assets | 6.24B | 1.35B | 2.85B | 3.89B | 1.08B |
| Cash, Cash Equivalents and Short-Term Investments | 5.18B | 600.05M | 2.40B | 2.31B | 504.36M |
| Total Debt | 166.94M | 0.00 | 7.10M | 16.05M | 32.09M |
| Total Liabilities | 328.14M | 251.97M | 148.62M | 135.91M | 118.89M |
| Stockholders Equity | 5.91B | 1.10B | 2.70B | 3.75B | 961.45M |
Cash Flow | |||||
| Free Cash Flow | -3.03B | -1.86B | -1.15B | -1.06B | -1.47B |
| Operating Cash Flow | -2.98B | -1.48B | -1.15B | -1.03B | -1.28B |
| Investing Cash Flow | -4.66B | 1.49B | 944.36M | -2.61B | -222.29M |
| Financing Cash Flow | 7.57B | -7.10M | -10.54M | 3.96B | 1.46B |
Suven Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹2.42T | 82.56 | ― | 0.32% | 16.35% | 26.84% | |
66 Neutral | ₹290.51B | 58.36 | ― | 0.15% | 78.33% | 182.61% | |
60 Neutral | ₹994.17B | 90.86 | ― | 0.11% | 22.62% | 114.66% | |
58 Neutral | ₹285.17B | -90.28 | ― | 0.07% | 0.78% | -420.81% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₹106.88B | -25.97 | ― | 11.14% | 17.26% | -68.16% | |
50 Neutral | ₹64.74B | 4.09 | ― | ― | 2855.80% | ― |
* General Sector Average
IN:SUVEN
Suven Life Sciences Limited
376.90
143.00
61.14%
IN:DIVISLAB
Divi's Laboratories Limited
9,305.00
3,303.71
55.05%
IN:LAURUSLABS
Laurus Labs Ltd.
1,868.25
974.03
108.93%
IN:NEULANDLAB
Neuland Laboratories Ltd.
22,872.35
8,459.54
58.69%
IN:PPLPHARMA
Piramal Pharma Limited
219.65
20.65
10.38%
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
206.10
64.95
46.01%
Suven Life Sciences Limited Corporate Events
Suven Life Sciences Opens Special Window for Physical Share Transfer Requests
Jul 14, 2026
Suven Life Sciences Limited has published newspaper advertisements in Business Standard and Nava Telangana announcing a special window for re-lodgment of transfer requests for physical share certificates. The move is in compliance with a recent SE...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.